Mobile

A phase II study of intratumoral application of L19IL2/L19TNF in melanoma patients in clinical stage III or stage IV M1a with presence of injectable cutaneous and/or subcutaneous lesions. Stud...

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-001991-13

A phase II study of intratumoral application of L19IL2/L19TNF in melanoma patients in clinical stage III or stage IV M1a with presence of injectable cutaneous and/or subcutaneous lesions. Studio di fase II di applicazione intratumorale di L19IL2/L19TNF nei pazienti con melanoma in stadio clinico III o IV M1a con presenza di lesioni iniettabili cutanee e/o sottocutanee

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Efficacy of L19IL2/L19TNF-treated lesions measured as : Rate of patients with complete response (CR) of L19IL2/L19TNF-treated lesions at week 12 (day 85). Efficacia del L19IL2/L19TNF sulle lesioni trattate, misurata in termini di: Tasso di pazienti con risposta completa (CR) di tutte le lesioni trattate con L19IL2/L19TNF alla settimana 12 (giorno 85).

Critère d'inclusion

  • Histologically-confirmed malignant melanoma of the skin with presence of injectable cutaneous and/or subcutaneous lesions either in clinical stage III or stage IV M1a,Melanoma maligno della pelle da conferma istologica di stadio clinico III o IV M1a con presenza di lesioni iniettabili cutanee e/o sottocutanee

Liens